1.16
+0.87%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bionano Genomics
From its filings with the US Securities and Exchange Commission
Bionano Genomics is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BNGO. The SEC classifies its business as laboratory analytical instruments. In the fiscal year to 31 December 2025, it reported revenue of $28.5m and a net loss of $26.4m. At that date it held total assets of $73.6m and shareholders' equity of $44.4m. By business, Product [Member] brought in 93.8% of revenue, followed by Product and Service, Other [Member] at 6.2%. By region, EMEA [Member] accounted for 49.5%, followed by Americas [Member] at 42.7% and Asia Pacific [Member] at 7.8%.
We are a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. Our mission is to transform the way the world sees the genome through optical genome mapping (“OGM”) solutions, nucleic acid extraction and purification systems, diagnostic services and software. We offer OGM solutions for applications across basic, translational and clinical research, and for other applications including bioprocessing. We offer a platform-agnostic software solution, which integrates next-generation sequencing (“NGS”), microarray and OGM data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. The Company also offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (“ITP”) technology. Through our Bionano Laboratories business, we also provide OGM-based diagnostic testing services.
We develop, manufacture, market and sell OGM systems, including the Saphyr® system and the Stratys system, which deliver OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (“SV”). These systems are used to identify structural changes in chromosomes, the study of which is known as cytogenetics, and to accelerate the search for answers in genetic disease and cancer applications as well as in applications for cell and gene therapy.
Quoted from its 10-K, filed 23 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 1 Aug 2018
- Employees
- 95
- Website
- bionanogenomics.com ↗
- Head office
- 9540 TOWNE CENTRE DRIVE, SAN DIEGO, CA, 92121
- Incorporated in
- DE
- Classification
- Laboratory Analytical Instruments
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Albert LudererIndependent Chairman of the Board$87,622
- Dr. R. Erik HolmlinPresident, Chief Executive Officer, Principal Financial Officer, Director, since 2011$989,677
- Mr. Mark OldakowskiChief Operating Officer$663,370
- Mr. Mark AdamchakVice President - Accounting, Principal Accounting Officer
- Mr. Jonathan DixonGeneral Counsel, Secretary
- Dr. Alka ChaubeyChief Medical Officer$661,908
- Dr. David BarkerIndependent Director$91,092
- Dr. Yvonne LinneyIndependent Director$61,857
- Ms. Hannah MamuszkaIndependent Director$64,357
- Dr. Aleksandar RajkovicIndependent Director$61,857
- Mr. Christopher TwomeyIndependent Director$76,857
- Dr. Kristiina VuoriIndependent Director$74,357
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 23
- Environment
- 4
- Social
- 19
- Governance
- 44
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bionano Genomics Inc employs 95 full-time employees in San Diego, US.
- The Saphyr system enables ultra-sensitive structural variation detection for cytogenetics.
- Lineagen, Inc. provides molecular diagnostics services for individuals in the US.
Weaknesses
- The company has 95 employees, which is fewer than industry standards for similar firms.
- The Saphyr system is limited to structural variation detection without broader genomic applications.
- Lineagen, Inc. operates only within the US, restricting global market reach.
Opportunities
- The Saphyr system can expand into new markets for structural variation detection.
- Lineagen, Inc. can grow its molecular diagnostics services internationally.
- Sequencing for Discovery Research can target new disease research areas.
Threats
- The company's IPO date of 1 August 2018 may affect long-term investor confidence.
- The Saphyr system faces competition from other genomic analysis tools.
- Lineagen, Inc. is limited to US operations, increasing vulnerability to domestic market changes.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.